Cañamero Lucía, Benito-Hernández Adalberto, González Elena, Escagedo Clara, Rodríguez-Vidriales María, García-Saiz María Del Mar, Valero Rosalía, Belmar Lara, de Cos María Angeles, Francia María Victoria, Ruiz Juan Carlos, Rodrigo Emilio
Immunopathology Group, Nephrology Department, Marqués de Valdecilla University Hospital-IDIVAL, University of Cantabria, 39012 Santander, Spain.
Immunopathology Group, Immunology Department, Marqués de Valdecilla University Hospital-IDIVAL, University of Cantabria, 39012 Santander, Spain.
Biomedicines. 2023 May 9;11(5):1410. doi: 10.3390/biomedicines11051410.
Measuring the non-pathogenic Torque Teno Virus (TTV) load allows assessing the net immunosuppressive state after kidney transplantation (KTx). Currently, it is not known how exposure to maintenance immunosuppression affects TTV load. We hypothesized that TTV load is associated with the exposure to mycophenolic acid (MPA) and tacrolimus. We performed a prospective study including 54 consecutive KTx. Blood TTV load was measured by an in-house PCR at months 1 and 3. Together with doses and trough blood levels of tacrolimus and MPA, we calculated the coefficient of variability (CV), time in therapeutic range (TTR) and concentration/dose ratio (C/D) of tacrolimus, and the MPA-area under the curve (AUC-MPA) at the third month. TTV load at the first and third month discriminated those patients at risk of developing opportunistic infections between months 1 and 3 (AUC-ROC 0.723, 95%CI 0.559-0.905, = 0.023) and between months 3 and 6 (AUC-ROC 0.778, 95%CI 0.599-0.957, = 0.028), respectively, but not those at risk of acute rejection. TTV load did not relate to mean tacrolimus blood level, CV, TTR, C/D and AUC-MPA. To conclude, although TTV is a useful marker of net immunosuppressive status after KTx, it is not related to exposure to maintenance immunosuppression.
测量非致病性微小病毒B19(TTV)载量有助于评估肾移植(KTx)后的净免疫抑制状态。目前,尚不清楚维持性免疫抑制暴露如何影响TTV载量。我们假设TTV载量与霉酚酸(MPA)和他克莫司的暴露有关。我们进行了一项前瞻性研究,纳入了54例连续的肾移植患者。在第1个月和第3个月通过内部PCR测量血液中的TTV载量。结合他克莫司和MPA的剂量及谷血药浓度,我们计算了他克莫司的变异系数(CV)、治疗范围内时间(TTR)和浓度/剂量比(C/D),以及第3个月时MPA的曲线下面积(AUC-MPA)。第1个月和第3个月时的TTV载量分别区分了在第1个月至第3个月以及第3个月至第6个月有发生机会性感染风险的患者(AUC-ROC分别为0.723,95%CI 0.559-0.905,P = 0.023;以及AUC-ROC为0.778,95%CI 0.599-0.957,P = 0.028),但不能区分有急性排斥反应风险的患者。TTV载量与他克莫司的平均血药浓度、CV、TTR、C/D及AUC-MPA均无关联。总之,尽管TTV是肾移植后净免疫抑制状态的有用标志物,但它与维持性免疫抑制暴露无关。